


What is claimed is:


1. A compound of formula I



I

5 or a pharmaceutically acceptable salt thereof wherein:

A is structure i, ii, iii, or iv



X¹ and Y¹ together form the group -C(=O)N(R⁵)- wherein X¹ is either C(=O) (and Y¹ is NR⁵) or X¹ is NR⁵ (and Y¹ is C(=O)).

10 Z¹ is

- (a) NHC(=O)R¹,
- (b) NHC(=S)R¹,
- (c) NH-het¹,
- (d) O-het¹,
- 15 (e) S-het¹, or
- (f) het²;

R¹ is

- (a) NH₂,
- 20 (b) NHC₁₋₄alkyl,
- (c) C₁₋₄alkyl,
- (d) C₂₋₄alkenyl,
- (e) -CH₂C(=O)C₁₋₄alkyl,
- (f) OC₁₋₄alkyl,
- 25 (g) SC₁₋₄alkyl, or
- (h) C₃₋₆cycloalkyl;

Each X, Y, and Z is independently selected from

- (e) H,
- (f) Cl,
- (g) F, or
- 5 (h) CH₃

R⁴ is


- (a) H,
- (b) C₁₋₄alkyl,
- (c) OC₁₋₄alkyl,
- 10 (d) SC₁₋₄alkyl, or
- (e) NHC₁₋₄alkyl;

R⁵ is

- (a) H,
- (b) C₁₋₄alkyl, or
- 15 (c) -(CH₂)_n-W₁-(CH₂)_n-Z³;

W₁ is

- (a) -CH₂-,
- (b) -CH=CH-,
- 20 (c) -C≡C-, or



Z³ is

- (a)
- 25 W₂ is
- (a) -O-,
 - (b) -N(R₂₅)-, or
 - (c) -C(=O)-N(R₂₅)-, wherein either the carbon or the nitrogen atom of the amide may be bound to a carbon atom of the phenyl ring of Z³;

R₂₂ is (CH₂)_nNR₂₃R₂₄, H, halo, C₁₋₄alkyl, -CN, -OH, -O-C₁₋₄alkyl, -S(O)_uC₁₋₄alkyl, and -C(=O)NH₂

- R₂₃ is H or C₁₋₄ alkyl;
- R₂₄ is H, C₁₋₄ alkyl, -S(O)₂-C₁₋₄alkyl, -C(=O)-C₁₋₄ alkyl, -C(=NH)-NH₂, -C(=O)-C(HR₂₆)-NR₂₇R₂₈;
- R₂₅ is H or C₁₋₄ alkyl;
- 5 R₂₆ is H, C₁₋₄ alkyl which can be optionally substituted by -OH, -NH₂, -NH-C(=NH)-NH₂, -SH, -SCH₃, -COOH, -C(O)NH₂, and phenyl which can be optionally substituted with -OH, imidazole, indole, or R₂₆ and R₂₇ together with the carbon atom to which R₂₆ attaches and the nitrogen atom to which R₂₇ attaches form a heterocycloalkyl;
- 10 R₂₇ is H or C₁₋₄ alkyl;
- R₂₈ is H, C₁₋₄ alkyl, -S(O)₂-C₁₋₄alkyl, -C(=O)-C₁₋₄ alkyl, -C(=NH)-NH₂, -C(=O)-C(HR₂₆)-NR₂₇R₂₇
- t is 0, 1;
- u is 0, 1, 2;
- 15 n is 1 or 2;
- het¹ is a C-linked five- (5) or six- (6) membered heterocyclic ring having 1-4 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen; het¹ being optionally substituted on one or more carbon atoms by 1-2 substituents selected from C₁-C₄alkyl, amino, C₁-C₄alkylamino, C₁-C₄alkyloxy, halogen -CN, =O, =S, and being optionally substituted with C₁-C₄alkyl;
- 20 het² is a N-linked five- (5) or six- (6) membered heterocyclic ring having at least one nitrogen atom, and optionally having one oxygen or sulfur atom; het² being optionally substituted on one or more carbon atoms by 1-2 substituents selected from C₁-C₄alkyl, amino, C₁-C₄alkylamino, C₁-C₄alkyloxy, halogen -CN, =O, =S, and being optionally substituted with C₁-C₄alkyl;
- 25 heterocycloalkyl is a four (5) or seven (7) membered saturated heterocyclic ring having 1-4 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen; heterocycloalkyl being optionally substituted on one or more carbon atoms by 1-2 substituents selected from C₁-C₄alkyl, amino, C₁-C₄alkylamino, C₁-C₄alkyloxy, halogen -CN, =O, =S, and being optionally substituted with C₁-C₄alkyl;
- 30 at each occurrence, alkyl, alkenyl, or cycloalkyl is optionally substituted with 1-3 halo, -OH, -OC₁₋₄alkyl, and
- Aryl refers to phenyl, biphenyl, or naphthyl, optionally substituted with halo,

C₁₋₄ alkyl, OH, OC₁₋₄ alkyl, -CH₂NH₂, -CH₂NH(C₁₋₄ alkyl), and S(O)_uC₁₋₄alkyl.

2. The compound of claim 1, wherein A is formula ii.
- 5 3. The compound of claim 1, wherein X is F.
4. The compound of claim 3, wherein Y is F.
5. The compound of claim 1, wherein Z¹ is -NH-C(O)R₁.
- 10 6. The compound of claim 5, wherein R₁ is selected from C₁₋₄alkyl optionally substituted with 1-3 halo.
7. The compound of claim 6, wherein R₁ is C₁₋₄alkyl substituted with 1-2 halo.
- 15 8. The compound of claim 1, wherein Z¹ is -NH-C(S)R₁.
9. The compound of claim 8, wherein R₁ is selected from C₁₋₄alkyl optionally substituted with 1-3 halo.
- 20 10. The compound of claim 9, wherein R₁ is C₁₋₄alkyl substituted with 1-2 halo.
11. The compound of claim 1, wherein Y¹ is -C(=O)- and X¹ is -N(R₅)-.
- 25 12. The compound of claim 1, wherein X¹ is -C(=O)- and Y¹ is -N(R₅)-.
13. A compound selected from the group consisting of
N-((5S)-3-[3-fluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide;
- 30 N-((5S)-3-[3-fluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanamide;
2,2-dichloro-N-((5S)-3-[3-fluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide;

- 2,2-difluoro-*N*-({(5*S*)-3-[3-fluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl} methyl)ethanethioamide;
- 2,2-difluoro-*N*-({(5*S*)-3-[3-fluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl} methyl)acetamide;
- 5 *N*-({(5*S*)-3-[3,5-difluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl} methyl)acetamide;
- 2,2-dichloro-*N*-({(5*S*)-3-[3,5-difluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl} methyl)acetamide;
- 10 *N*-({(5*S*)-3-[3,5-difluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl} methyl)-2,2-difluoroethanethioamide;
- 15 *N*-({(5*S*)-3-[3,5-difluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl} methyl)-2,2-difluoroacetamide;
- 20 *N*-({(5*S*)-2-oxo-3-[4-(6-oxopiperidin-3-yl)phenyl]-1,3-oxazolidin-5-yl} methyl)acetamide;
- 25 *N*-({(5*S*)-2-oxo-3-[4-(6-oxopiperidin-3-yl)phenyl]-1,3-oxazolidin-5-yl} methyl)propanamide;
- 30 2,2-difluoro-*N*-({(5*S*)-2-oxo-3-[4-(6-oxopiperidin-3-yl)phenyl]-1,3-oxazolidin-5-yl} methyl)ethanethioamide;
- 2,2-difluoro-*N*-({(5*S*)-2-oxo-3-[4-(6-oxopiperidin-3-yl)phenyl]-1,3-oxazolidin-5-yl} methyl)ethanethioamide;
- ({(5*S*)-3-[4-(1-methyl-6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl} methyl)acetamide;
- 25 *N*-({(5*S*)-3-[3-fluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl} methyl)acetamide;
- 30 *N*-({(5*S*)-3-[3-fluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl} methyl)propanamide;
- 2,2-difluoro-*N*-({(5*S*)-3-[3-fluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl} methyl)ethanethioamide;
- N*-({(5*S*)-3-[3,5-difluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl} methyl)acetamide;

- N-((5S)-3-[3,5-difluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanamide;
- N-((5S)-3-[3,5-difluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)-2,2-difluoroethanethioamide;
- 5 N-((5S)-2-oxo-3-[4-(2-oxopiperidin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)acetamide;
- 2,2-difluoro-N-((5S)-2-oxo-3-[4-(2-oxopiperidin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)ethanethioamide;
- N-((5S)-2-oxo-3-[4-(2-oxopiperidin-4-yl)phenyl]-1,3-oxazolidin-5-10 yl}methyl)propanamide; and
- N-((5S)-3-[4-(1-methyl-2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide.

14. A compound selected from the group consisting of
- 15 N-((5S)-3-[3-fluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide; N-((5S)-3-[3-fluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanamide;
- N-((5S)-3-[3,5-difluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide;
- 20 N-((5S)-2-oxo-3-[4-(6-oxopiperidin-3-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)acetamide;
- N-((5S)-2-oxo-3-[4-(6-oxopiperidin-3-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)propanamide;
- ((5S)-3-[4-(1-methyl-6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-25 yl}methyl)acetamide;
- N-((5S)-3-[3-fluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide;
- N-((5S)-3-[3-fluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanamide;
- 30 N-((5S)-3-[3,5-difluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide;
- N-((5S)-3-[3,5-difluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanamide;

- N-((5S)-2-oxo-3-[4-(2-oxopiperidin-4-yl)phenyl]-1,3-oxazolidin-5-yl} methyl)acetamide;
- N-((5S)-2-oxo-3-[4-(2-oxopiperidin-4-yl)phenyl]-1,3-oxazolidin-5-yl} methyl)propanamide; and
- 5 N-((5S)-3-[4-(1-methyl-2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl} methyl)acetamide.
15. A compound selected from the group consisting of
 2,2-dichloro-N-((5S)-3-[3-fluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-
 10 oxazolidin-5-yl} methyl)acetamide;
 2,2-difluoro-N-((5S)-3-[3-fluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-
 oxazolidin-5-yl} methyl)ethanethioamide;
 2,2-difluoro-N-((5S)-3-[3-fluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-
 oxazolidin-5-yl} methyl)acetamide;
- 15 2,2-dichloro-N-((5S)-3-[3,5-difluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-
 oxazolidin-5-yl} methyl)acetamide;
 N-((5S)-3-[3,5-difluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-
 yl} methyl)-2,2-difluoroethanethioamide;
 N-((5S)-3-[3,5-difluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-
 20 yl} methyl)-2,2-difluoroacetamide;
- 2,2-dichloro-N-((5S)-2-oxo-3-[4-(6-oxopiperidin-3-yl)phenyl]-1,3-oxazolidin-5-
 yl} methyl)acetamide;
- 2,2-difluoro-N-((5S)-2-oxo-3-[4-(6-oxopiperidin-3-yl)phenyl]-1,3-oxazolidin-5-
 yl} methyl)ethanethioamide;
- 25 2,2-difluoro-N-((5S)-2-oxo-3-[4-(6-oxopiperidin-3-yl)phenyl]-1,3-oxazolidin-5-
 yl} methyl)ethanethioamide;
 2,2-difluoro-N-((5S)-3-[3-fluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-
 oxazolidin-5-yl} methyl)ethanethioamide;
- N-((5S)-3-[3,5-difluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-
 30 yl} methyl)-2,2-difluoroethanethioamide; and
 2,2-difluoro-N-((5S)-2-oxo-3-[4-(2-oxopiperidin-4-yl)phenyl]-1,3-oxazolidin-5-
 yl} methyl)ethanethioamide.

16. The compound 5-{2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl}piperidin-2-one.
17. A method for the treatment of microbial infections in mammals comprising
5 administration of an effective amount of compound of claim 1 to said mammal.
18. The method of claim 17 wherein said compound of claim 1 is administered to
the mammal orally, parenterally, transdermally, or topically in a pharmaceutical
composition.
10
19. The method of claim 18 wherein said compound is administered in an amount
of from about 0.1 to about 100 mg/kg of body weight/day.
20. The method of claim 18 wherein said compound is administered in an amount
15 of from about 1 to about 50 mg/kg of body weight/day.
21. A pharmaceutical composition comprising a compound of claim 1 and a
pharmaceutically acceptable carrier.